Illumina, Inc. (ILMN)
| Market Cap | 26.71B |
| Revenue (ttm) | 4.39B |
| Net Income (ttm) | 853.00M |
| Shares Out | 151.30M |
| EPS (ttm) | 5.52 |
| PE Ratio | 32.00 |
| Forward PE | 32.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,196,196 |
| Open | 176.07 |
| Previous Close | 177.65 |
| Day's Range | 173.24 - 179.93 |
| 52-Week Range | 88.00 - 182.84 |
| Beta | 1.49 |
| Analysts | Buy |
| Price Target | 151.68 (-14.09%) |
| Earnings Date | Jul 30, 2026 |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price target is $151.68, which is a decrease of -14.09% from the latest price.
News
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc....
Illumina (ILMN): Bullish Structure Builds After Breakout
Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can gener...
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN)...
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's hi...
David P. King elected to Illumina's Board of Directors
Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today confirmed th...
Illumina Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals preliminarily approved. No questions were submitted during the Q&A, and forward-looking statements were qualified by reference to SEC filings.
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
SAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expandin...
What CEOs from Tesla, Nvidia and over a dozen other companies hope to gain by joining Trump in China
A key part of President Donald Trump's visit to China this week is his effort to bring along with him at least 17 executives from prominent U.S. companies. Here's what it means for them.
Illumina Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong clinical growth and robust NovaSeq X demand, prompting raised full-year guidance for revenue, margin, and EPS. Clinical markets remain the primary growth driver, while research and applied markets are cautious amid funding uncertainty.
Illumina Earnings release: Q1 2026
Illumina released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Illumina Slides: Q1 2026
Illumina has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Illumina Quarterly report: Q1 2026
Illumina has published its Q1 2026 quarterly earnings report on April 30, 2026.
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 202...
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research New pangenome representation, default personalizati...
Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center f...
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. O...
Illumina Proxy statement: Proxy filing
Illumina filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Illumina Proxy statement: Proxy filing
Illumina filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Illumina Announces Changes to Board of Directors
David P. King nominated to support next phase of growth and innovation; Frances Arnold, Robert S. Epstein, and Gary S.
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collabo...
Illumina advances preventive genomics through strategic consortium with Veritas Genetics
New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention SAN DIEGO, March 16, 2026 /PRNewswire/ -- ...
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, Mar...